Log in

Axsome Therapeutics Inc (NASDAQ:AXSM) Director Acquires $51,025.00 in Stock

Posted on Tuesday, June 30th, 2020 by MarketBeat

Axsome Therapeutics Inc (NASDAQ:AXSM) Director Mark Coleman bought 650 shares of the company's stock in a transaction dated Monday, June 29th. The stock was bought at an average price of $78.50 per share, for a total transaction of $51,025.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Axsome Therapeutics stock opened at $76.36 on Tuesday. The business's fifty day simple moving average is $79.83 and its 200 day simple moving average is $79.86. The firm has a market capitalization of $3.18 billion, a P/E ratio of -29.83 and a beta of 3.14. Axsome Therapeutics Inc has a 12 month low of $13.64 and a 12 month high of $109.94. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.10.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.88) EPS for the quarter, missing the Zacks' consensus estimate of ($0.60) by ($0.28). Analysts predict that Axsome Therapeutics Inc will post -2.76 EPS for the current fiscal year.

AXSM has been the topic of a number of recent research reports. Cowen initiated coverage on Axsome Therapeutics in a report on Tuesday, April 14th. They issued an "outperform" rating and a $95.00 target price on the stock. William Blair restated a "buy" rating on shares of Axsome Therapeutics in a report on Monday, April 6th. LADENBURG THALM/SH SH raised their target price on Axsome Therapeutics from $165.00 to $186.00 and gave the company a "buy" rating in a report on Monday, April 27th. SunTrust Banks raised their target price on Axsome Therapeutics from $145.00 to $200.00 and gave the company a "buy" rating in a report on Monday, April 27th. Finally, HC Wainwright restated a "buy" rating on shares of Axsome Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of "Buy" and a consensus price target of $137.30.

Institutional investors and hedge funds have recently modified their holdings of the business. Total Clarity Wealth Management Inc. bought a new stake in shares of Axsome Therapeutics in the fourth quarter valued at $25,000. GQ Asset Management LLC bought a new stake in shares of Axsome Therapeutics in the first quarter valued at $56,000. Exane Derivatives bought a new stake in shares of Axsome Therapeutics in the first quarter valued at $76,000. Banque Cantonale Vaudoise bought a new stake in shares of Axsome Therapeutics in the first quarter valued at $86,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Axsome Therapeutics by 9.4% in the first quarter. Meeder Asset Management Inc. now owns 1,558 shares of the company's stock valued at $92,000 after buying an additional 134 shares during the period. Hedge funds and other institutional investors own 66.19% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Further Reading: How to Invest in Stocks with Increasing Dividends

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Dividend Aristocrat Stocks to Buy Now

The stock market is having its worst week since the financial crisis. For some investors, a flight to safety has them getting out of the market. But other investors are taking a flight to quality. And when it comes to quality in equities, these are the moments when dividend stocks shine.

Already JPMorgan Chase (NYSE:JPM), Morgan Stanley (NYSE:MS) and Goldman Sachs (NYSE:GS) are projecting that the coronavirus may wipe out corporate earnings growth for 2020. If investors can’t count on their equities to provide capital gains, they look to dividends to boost their total return.

But like any investment, not all dividend stocks are alike. Some of the best dividend stocks are the dividend aristocrats. By definition, for a company to become a dividend aristocrat, they must have at least 25 consecutive years of dividend growth (not just issued a dividend). These companies have a proven track record of weathering market turbulence and delivering solid performance. And, right now, there are only 64 of these companies. In this presentation, we’ll give you 10 dividend aristocrat stocks you can invest in right now.

View the "10 Dividend Aristocrat Stocks to Buy Now".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.